PRNB - Principia Biopharma: High Risk/Low Reward
Principia Biopharma (PRNB) is a San Francisco-based clinical-stage biotechnology company. The company is focused on the development of Bruton's tyrosine kinase ((BTK)) inhibitors as a potential treatment for rare autoimmune disorders.
Source: Principia Biopharma corporate presentation
In this article, I will try to explain why I am skeptical about the likelihood of encouraging clinical trial results and why the probability of future commercial success in pemphigus treatment is foggy.
In addition, in the second indication (immune thrombocytopenia), the company's drug candidate is aimed to address a much smaller number of potential patients than the company